↓ Skip to main content

Dove Medical Press

Article Metrics

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, March 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
36 Mendeley
Title
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
Published in
International Journal of Chronic Obstructive Pulmonary Disease, March 2012
DOI 10.2147/copd.s19805
Pubmed ID
Authors

Kenneth Chapman, Ribeiro

Abstract

Long-acting bronchodilators have been shown to improve multiple clinical outcomes in chronic obstructive pulmonary disease (COPD) including lung function, symptoms, dyspnea, quality of life, and exacerbations. Indacaterol is a novel, inhaled, long-acting β2-agonist providing 24-hour bronchodilation with once-daily dosing. It is currently approved for the maintenance treatment of COPD to be administered as 150 or 300 μg once-daily doses as licensed in many countries and 75 μg as licensed in the US by means of a single-dose dry powder inhaler. The data from clinical development support a favorable safety and tolerability profile within the β2-agonist drug class, with no relevant issues identified. Current evidence indicates that indacaterol is suitable for use as first-line monotherapy in COPD patients with moderate disease (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) and beyond that do not require an inhaled corticosteroid (ICS) as per GOLD guidelines, or in combination with an ICS in severe or very severe patients with repeated exacerbations. Data from trials with the novel once-daily β2-agonist, indacaterol, indicate superior bronchodilation and clinical efficacy over twice-daily long-acting β2-agonists and at least equipotent bronchodilation as once-daily tiotropium. Bronchodilators are central in the symptomatic management of COPD. It is likely that once-daily dosing of a bronchodilator would be a significant convenience and probably a compliance-enhancing advantage, leading to improved overall clinical outcomes in patients with COPD.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 6%
Brazil 1 3%
Unknown 33 92%

Demographic breakdown

Readers by professional status Count As %
Other 7 19%
Student > Bachelor 4 11%
Researcher 4 11%
Student > Master 3 8%
Student > Doctoral Student 3 8%
Other 12 33%
Unknown 3 8%
Readers by discipline Count As %
Medicine and Dentistry 25 69%
Agricultural and Biological Sciences 2 6%
Unspecified 1 3%
Nursing and Health Professions 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 4 11%
Unknown 2 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2012.
All research outputs
#6,748,476
of 12,450,995 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#735
of 1,517 outputs
Outputs of similar age
#54,981
of 120,269 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#20
of 35 outputs
Altmetric has tracked 12,450,995 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,517 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 120,269 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.